Thrombolytic Therapy: Overview of Results in Major Vascular Occlusions

Victor J Marder

doi:10.1055/s-0038-1642660

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1995; 74(01): 101-105
DOI: 10.1055/s-0038-1642660

Symposium

Thrombolytic Thearpy

Schattauer GmbH Stuttgart

Thrombolytic Therapy: Overview of Results in Major Vascular Occlusions

Authors

Victor J Marder

Hematology Unit, Department of Medicine, University of Rochester School of Medicine & Dentistry Rochester, New York, NY, USA

Abstract

PDF Download

PDF (371 kb)

References

References
1 Marder VJ, Sherry S. Thrombolytic therapy: Current status. N Engl J Med 1988; 318: 1512-1585
2 Verstraete M. Biochemical and clinical aspects of thrombolysis. Seminars in Hematology 1978; 15: 35-35
3 European Co-operative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction N Engl J Med 1979; 301: 797-797
4 DeWood MA, Spores J, Notske R. et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-897
5 Rentrop P, Blanke H, Karsch KR. et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. din Cardiol 1979; 2: 354-354
6 Stampfer MJ, Goldhaber SZ, Yusuf S. et al. Effect of intravenous streptokinase on acute myocardial infarction: Pooled results from randomized trials. N Engl J Med 1982; 307: 1180-1180
7 Fibrinolytic Therapy Trialists’ (FT 1) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and majormorbidity results from all randomi sed trials of more than 1000 patients. Lancet. 1994 343. 311-311
8 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardica (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-397
9 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988 2. 349-349
10 Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM. Hampton JR for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET) Lancet 1988; 2: 525-525
11 AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial: AIMS Trial study group. Lancet. 1988 1. 545-545
12 AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial study group Lancet 1990 335. 427-427
13 Wilcox RG, von der Lippe, Olsson CG, Jensen G, Skene AM, Hampton JR. For the Anglo-Scandinavian Study of Early Thrombolysis. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study: Anglo-Scandinavian Study of Early Thrombolysis Lancet 1990; 335: 1175-1175
14 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study Lancet 1987; 2: 871-871
15 Gore JM, Sloan M, Price TR, Randall AM Y, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML. and the TIMI Investigators Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in myocardial infarction phase II, pilot and clinical trial Circulation 1991; 83: 448-448
16 Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, Boersma E, Franzosi MG, Califf R, Schroder R, Braunwald E. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523-1523
17 Blaisdell FW, Steele M, Allen RE. Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery 1978; 84: 822-822
18 Ricotta JJ, Green RM, De Weese JA. Use and limitations of thrombolytic therapy in the treatment of peripheral arterial ischemia: results of a multi-institutional questionnaire. J Vase Surg 1987; 6: 45-45
19 Comerota AJ. Intra-arterial Thrombolytic Therapy. In: Thrombolytic Therapy. Comerota AJ. ed. Grune and Stratton; New York, NY: 1988. pp 125-152
20 Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV U, Gutierrez OS, Mazione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vase Surg 1994; 19: 1021-1021
21 Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111: 31-31
22 The Urokinase Pulmonary Embolism Trial: A national cooperative study. Circulation 1973; 47 (11) 1-1
23 Dalen JE, Alpeit JS. Natural hi story of pulmonary embolism. In: Pulmonary Emboli. Sasahara AA, Sonnenblick EH, Lesch M. eds. Grune and Stratton; New York, NY: 1975. pp 77-88
24 Goldhaber SZ. Thrombolysis for pulmonary embolism. Progress in Cardiovascular Diseases 1991; 34: 113-113
25 Urokinase Pulmonaiy Embolism Trial: Phase 1 results. JAMA 1970; 214: 2163-2163
26 Hyers TM, Stengle JM, Sherry S. Editorial. Treatment of pulmonary embolism with urokinase results of clinical trial (Phase 1) Circulation 1970; 42: 979-979
27 Marder VJ. Editorial. Are we using fibrinolytic agents often enough? Ann IntMed 1980; 93: 136-136
28 Moser KM. State of the Art. Pulmonary embolism American Review of Respiratory Disease 1977; 115: 829-829
29 Hirsh J, Marder VJ, Salzman ED, Hull R. Treatment of venous thromboembolism. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder JV, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994. pp 1346-66
30 Lensing AW A, Hirsh J. Natural histoiy of minimal calf DVT. Rationale and results of thrombolytic therapy. In: Vascular Diagnosis.Bernstein. Mosby-Yearbook St. ed. Louis, MO: 1994. pp 779-781
31 Immelman EJ, Jeffery PC. The post-phlebitic syndrome. Pathophysiology, prevention and management Clin Chest Med 1984; 5: 537-537
32 Francis CW, Marder VJ. Fibrinolytic therapy for venous thrombosis. Progress in Cardiovascular Diseases 1991; 34: 193-193
33 Goldhaber SZ, Meyerovitz MF, Green D. et al. Randomized controlled trial of tissue plasminogen activator in proximal DVT. Am J Med 1990; 88: 235-235
34 Marder VJ, Soulen RL, Atichaitakam V. et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1018
35 Elliot MS, Immelman EJ, Jeffrey P. et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trial. Br J Surg 1979; 66: 838-838
36 Turpie AG G, Levine MN, Hirsh J. et al. Tissue plasminogen activator vs heparin in DVT. Results of a randomized trial Chest 1990; 97: 172S-172S
37 Bieger R, Boekhout-Musseit RJ, Hohmann F. et al. Is streptokinase useful in the treatment of deep venous thrombosis?. Acta Med Scand 1976; 199: 81-81
38 Amesen H, Hoiseth LyB. Streptokinase or heparin in the treatment of deep vein thrombosis. Acta Med Scand 1982; 211: 65-65
39 Thrombolytic therapy in thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93: 141-141
40 Weinmann EE, Salzman EW. Deep-vein thrombosis. NEJM 1994; 331: 1630-1630
41 Urokinase-Streptokinase Embolism Trial. Phase 2 Results. A cooperative Study. JAMA 1974 229. 1606-1606
42 Goldhaber SZ, Kessler CM, Heit JA. et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988; 2: 293-293
43 Goldhaber SZ, Kessler CM, Heit JA, Elliott CG, Friedenberg WR, Heiselman DE, Wilson DB, Parker JA, Bennett D, Feldstein ML, Selwyn AP, Ducksoo K, Sharma GV R K, Nagel JS, Meyerovitz MF. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial. JACC 1992; 20: 24-24
44 Verstraete M, Miller GA H, Bounameaux H, Charbonnier B, Colie JP, Lecorf G, Marbet GA, Mombaeits P, Ols son CG. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-353
45 Dardik H, Sussman BC, Kahn M. et al. Lysis of arterial clot by intravenous or intraarterial administration of streptokinase. Surg Gynecol Obstet 1984; 158: 137-137
46 Hallatt Jr JW, Yrizarry JM, Greenwood LH. Regional low-dosage thrombolytic therapy for peripheralarterial occlusions. Surg Gynecol Obstet 1983; 156: 148-148
47 Gardiner Jr GA, Koltun W, Kandarpa K. et al. Thrombolysis of occluded femoropopliteal grafts. AJR 1986; 147: 621-621
48 Belkin M, Belkin B, Bucknam CA, Straub JJ, Lowe R. Intraarterial fibrinolytic therapy -efficacy of streptokinase vs. urokinase. Arch Surg 1986; 121: 769-769
49 McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: Improved results using high-dose urokinase. AJR 1985; 144: 769-769
50 Strandness Jr DE, Salzman EW, Shortell CK, Marder VJ. Management of peripheral arterial disease. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder JV, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994. pp 1396-1408
51 The STILE Investigators. Results of a prospective randomized trialevaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial Annals of Surgery 1994 220. 251-251
52 Gruppo Italiano per lo Studio della Soprawivenza nell’Infarto Miocardico (GISSI). GISSI-2 a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction Lancet 1990; 336: 65-65
53 The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990 336. 71-71
54 ISIS-3 (Third International Study of Infarct Survival) Collaborative Study Group. ISIS-3 a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-753
55 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 1993; 329: 673-673
56 The Global Use of Strategies to open Occluded Coronary Arteries (GUSTO) Ha Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-1631
57 Antman EM for the TIMI 9A Investigators: Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9 A Trial. Circulation 1994; 90: 1624-1624
58 Grines CL, Nissen SE, Booth DC. et al. A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84: 540-540
59 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival afteracute myocardial infarction N Engl J Med 1993; 329: 1615-1615
60 Sherry S, Marder VJ. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction. Ann IntMed 1991; 114: 417-417